LLBO Lifeline Biotech Inc (CE)

Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) today announced that it has been awarded U.S. Patent 7,384,401 B2 on its OvaScope� technology. The OvaScope� has been designed and developed to assist in the early detection of ovarian cancer. Historically, ovarian cancer has not been detected until its advanced stages, which has led to poor survival rates.

To date, the preliminary testing has proved to be very promising. Lifeline will begin taking the next steps toward bringing the OvaScope to market upon completion of its current review of the testing data results and the market for the product.

Jim Holmes, CEO of Lifeline Biotechnologies, stated, �It is estimated that 1 in 70 women in the United States will develop ovarian cancer during their lifetime. Unfortunately, detection usually occurs in the late stages, leading to poor survival rates. With a U.S. patent and very encouraging results from our preliminary testing, we feel the OvaScope has the ability to address this issue and make tremendous strides towards early detection of ovarian cancer. If we can detect this cancer in its early stages, it will dramatically increase the potential survival rate for women.�

Lifeline Biotechnologies has in the past year filed for a patent on the recent technological advancements of the First Warning System�, which has achieved the robust capability of identifying and classifying abnormalities of the breast with sensitivities of 95% to 100% and specificities of 87% to 90%. Currently, it is a well known fact that mammograms are missing an estimated 30% to 40% of the breast cancers.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company�s product and regulatory and shareholder approval for anticipated actions.

Lifeline Biotech (CE) (USOTC:LLBO)
Historical Stock Chart
From Feb 2025 to Mar 2025

Lifeline Biotech (CE) (USOTC:LLBO)
Historical Stock Chart
From Mar 2024 to Mar 2025